Showing 20 of 223 recruiting trials for “acute-promyelocytic-leukemia”
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
🏥 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Oct 2024View details ↗
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
👨⚕️ He Huang, MD, First Affiliated Hospital of Zhejiang University📍 1 site📅 Started Oct 2024View details ↗
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
👨⚕️ Somedeb Ball, MD, Vanderbilt University/Ingram Cancer Center📍 1 site📅 Started Aug 2024View details ↗
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
👨⚕️ Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06377579 ↗
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
👨⚕️ Pierre PETERLIN, Dr, French Innovative Leukemia Organisation📍 21 sites📅 Started Jul 2024View details ↗
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
👨⚕️ Xianmin Song, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jul 2024View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →